Patients treated with RFA exhibit elevated levels of interleukin-6 (IL-6) and local or systemic inflammatory responses, indicating that the inflammatory response significantly contributes to rapid tumor progression following RFA (Douglas et al., 2008; Chu et al., 2018; Ali et al., 2022; Tan et al., 2018). Here, IL6 is linked to neoplasm.